Immunotherapies with agents preventing the binding of the immune checkpoint PD-1 to PD-L1 was found to be efficacious in BC (4, 5), which support a great need to fully understand the variations in TIL-B-mediated responses. The gene discussed is CD274; the disease is breast cancer.